J&J’s Sirturo Gets Panel Endorsement For Accelerated OK, Even As FDA Broaches Full Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Anti-Infective Drugs Advisory Committee was fully satisfied with “sputum culture conversion” as a surrogate endpoint for accelerated approval, but turned back a last-minute question from FDA on traditional full approval for the tuberculosis drug bedaquiline.
You may also be interested in...
Emerging Markets Focused J&J’s Sirturo Approval Tied To Expansive Post-Marketing Study Program
The first drug approved for multi-drug resistant tuberculosis, Sirturo obtained accelerated approval based on data from two Phase II studies, but has a troubling safety database, including 10 deaths in the treatment arm of its Phase II program.
J&J’s Sirturo Approval Tied To Expansive Post-Marketing Study Program
The first drug approved for multi-drug resistant tuberculosis, Sirturo obtained accelerated approval based on data from two Phase II studies, but has a troubling safety database, including 10 deaths in the treatment arm of its Phase II program.
Market Access Strategies: Pending Approvals, J&J Plans Cautious Steps For Access To Anti-TB Drug Bedaquiline
In an interview, Janssen Chairman Paul Stoffels discusses market access issues related to bedaquiline and J&J’s recent decision to free up patents on its HIV therapy Prezista.